A UNSW Sydney-led team of scientists has made an advance that could eventually lead to a cure for sickle cell anaemia and other blood disorders.
By introducing a beneficial natural mutation into blood cells using the gene-editing technique CRISPR, a UNSW Sydney-led team of scientists has been able to switch on production of foetal haemoglobin – an advance that could eventually lead to a cure for sickle cell anaemia and other blood disorders.
People with thalassaemia or sickle cell anaemia have damaged adult haemoglobin – the vital molecule that picks up oxygen in the lungs and transports it around the body – and they require life-long treatment with blood transfusions and medication.
However, people with these diseases who also carry the beneficial natural mutation – known as British-198 – have reduced symptoms, because the mutation switches on the foetal haemoglobin gene that is normally turned off after birth.
The extra foetal haemoglobin in their blood, which has a very strong affinity for oxygen, does the work of the defective adult haemoglobin.
“With CRISPR gene-editing we can now precisely cut and alter single genes within our vast genome,” says study senior author and UNSW molecular biologist Professor Merlin Crossley.
“Our laboratory has shown that introducing the beneficial mutation British-198 into blood cells using this technology substantially boosts their production of foetal haemoglobin.
“Because this mutation already exists in nature and is benign, this ‘organic gene therapy’ approach should be effective and safe to use to treat, and possibly cure serious blood disorders. However, more research is still needed before it can be tested in people,” he says.
The study by scientists from UNSW, the Japanese Red Cross Society and the RIKEN BioResource Centre in Japan, is published in the journal Blood.
The beneficial British-198 mutation, which was first identified in a large British family in 1974, involves a change in just a single letter of the genetic code.
Carriers of this mutation have foetal haemoglobins levels as high as 20% of total haemoglobin, while most people’s foetal haemoglobin levels fall to about 1% of total haemoglobin after birth.
The researchers also discovered how this British-198 mutation works. They found it creates a new binding site for a protein called KLF1 that turns blood genes on.
Mutations affecting adult haemoglobin production are among the most common of all genetic variations, with about 5% of the world’s population carrying a defective gene.
“To turn the new gene editing approach into a therapy for blood disorders, the British-198 mutation would have to be introduced into blood-forming stem cells from the patient,” says Professor Crossley.
“A large number of stem cells would have to be edited in order to repopulate the patients’ blood with genetically enhanced cells.”
The Latest on: Genome therapy
- Adverum Announces Clinical Hold, But It Should Not Hinder Its Gene Therapy Path on April 17, 2019 at 7:53 am
Regenxbio Inc. (RGNX) has its own gene therapy product ... and A1AT deficiency (rare genetic disorder caused by Alpha-1 deficiency, leading to liver/lung disease). I believe that Adverum will ... […]
- Author Jamie Metzl says the "genetic revolution" could threaten national security on April 17, 2019 at 3:58 am
Could gene therapy cure sickle cell anemia? Recent advances in reproductive technologies and genetic screening hold tremendous promise for the elimination of harmful inherited diseases, but they also ... […]
- Precision BioSciences Announces Dosing of First Patient in Off-The-Shelf CAR T Cell Therapy Phase 1/2a Clinical Trial on April 17, 2019 at 2:30 am
DURHAM, N.C., April 17, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company ... as an off-the-shelf cell therapy. The first patient dosed ... […]
- Genetic sequencing uncovers causes for mysterious liver disease in adults on April 16, 2019 at 6:36 am
Genetic sequencing for individuals with liver disease has been ... With this accurate diagnosis, the patient is being treated with leptin replacement therapy, which has allowed her to reduce her ... […]
- Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy on April 15, 2019 at 8:52 pm
April 15, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (FCSC), a cell and gene therapy company focused ... life-threatening genetic disorder diagnosed at infancy with no cure or treatment ... […]
- Health Watch: Gene Therapy Restores Ro'Nylah's Sight! on April 15, 2019 at 6:29 pm
MIAMI, Fla. -- One in 40,000 children are born with a rare genetic disorder that robs them of their vision. Now, surgeons are performing an innovative gene therapy treatment that is restoring the ... […]
- New study first to identify cause of rare genetic metabolic disorder on April 15, 2019 at 1:42 pm
In this important study, researchers found an unusual genetic mutation behind three children's undiagnosed ... further research that could lead to new interventions such as gene therapy aimed at ... […]
- Fibrocell, Castle Creek ink rare disease gene therapy pacts worth up to $135M on April 15, 2019 at 8:18 am
Fibrocell is enlisting Castle Creek Pharma’s help to push its midphase gene therapy for a rare genetic disorder through the clinic and onto the market. Castle Creek is licensing the program and will ... […]
- Fibrocell in $135 million deal to bring skin-disease gene therapy to market on April 15, 2019 at 7:36 am
said it has signed a collaboration deal with Parsippany-based Castle Creek Pharmaceuticals “to develop and commercialize its lead gene therapy candidate FCX-007, for the treatment of recessive ... […]
- Another Week, Another Gene Therapy Buyout: Catalent Pays $1.2B for Paragon on April 15, 2019 at 5:13 am
In a gene therapy procedure, these vectors—engineered viruses—are filled with genetic blueprints and infused into a patient’s body. Those viruses then deliver their instructions, which tell ... […]
via Google News and Bing News